2. Academic Validation
  3. Donated chemical probes for open science

Donated chemical probes for open science

  • Elife. 2018 Apr 20;7:e34311. doi: 10.7554/eLife.34311.
Susanne Müller 1,  Suzanne Ackloo 2,  Cheryl H Arrowsmith 3,  Marcus Bauser 4,  Jeremy L Baryza 5,  Julian Blagg 6,  Jark Böttcher 7,  Chas Bountra 8,  Peter J Brown 2,  Mark E Bunnage 5,  Adrian J Carter 9,  David Damerell 8,  Volker Dötsch 10 11,  David H Drewry 12,  Aled M Edwards 2,  James Edwards 13,  Jon M Elkins 8,  Christian Fischer 14,  Stephen V Frye 15,  Andreas Gollner 16,  Charles E Grimshaw 17,  Adriaan IJzerman 18,  Thomas Hanke 1,  Ingo V Hartung 4,  Steve Hitchcock 19,  Trevor Howe 20,  Terry V Hughes 20,  Stefan Laufer 21,  Volkhart Mj Li 22,  Spiros Liras 23,  Brian D Marsden 8 24,  Hisanori Matsui 25,  John Mathias 23,  Ronan C O'Hagan 14,  Dafydd R Owen 23,  Vineet Pande 26,  Daniel Rauh 27,  Saul H Rosenberg 28,  Bryan L Roth 29,  Natalie S Schneider 1,  Cora Scholten 4,  Kumar Singh Saikatendu 19,  Anton Simeonov 30,  Masayuki Takizawa 31,  Chris Tse 28,  Paul R Thompson 32,  Daniel K Treiber 33,  Amélia Yi Viana 9,  Carrow I Wells 12,  Timothy M Willson 12,  William J Zuercher 12,  Stefan Knapp 1,  Anke Mueller-Fahrnow 4
Affiliations

Affiliations

  • 1 Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • 2 Structural Genomics Consortium, University of Toronto, Toronto, Canada.
  • 3 Department of Medical Biophysics, University of Toronto, Toronto, Canada.
  • 4 Drug Discovery Pharmaceuticals, Bayer AG, Berlin, Germany.
  • 5 Vertex Pharmaceuticals, Boston, United States.
  • 6 Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
  • 7 Discovery Research, Boehringer Ingelheim, Vienna, Austria.
  • 8 Structural Genomics Consortium, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • 9 Discovery Research, Boehringer Ingelheim, Ingelheim am Rhein, Germany.
  • 10 Institute of Biophysical Chemistry, Goethe-University, Frankfurt am Main, Germany.
  • 11 Center for Biomolecular Magnetic Resonance, Goethe University, Frankfurt am Main, Germany.
  • 12 Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States.
  • 13 Janssen Pharmaceutical Research and Development LLC, Spring House, United States.
  • 14 Merck & Co., Inc., Boston, United States.
  • 15 Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States.
  • 16 Discovery Research, Boehringer Ingelheim, Biberach an der Riss, Germany.
  • 17 Ched Grimshaw Consulting, LLC, Poway, United States.
  • 18 Division of Medicinal Chemistry, Leiden University, Leiden, Netherlands.
  • 19 Takeda California Inc., San Diego, United States.
  • 20 J&J Innovation Centre, London, United Kingdom.
  • 21 Department of Pharmaceutical Chemistry, Eberhard Karls Universität Tübingen, Tübingen, Germany.
  • 22 Drug Discovery Pharmaceuticals, Bayer AG, Wuppertal, Germany.
  • 23 Worldwide Medicinal Chemistry, Pfizer, Cambridge, United States.
  • 24 Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.
  • 25 Takeda Pharmaceutical Company Ltd, Fujisawa, Japan.
  • 26 Discovery Sciences, Janssen-Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium.
  • 27 Fakultät für Chemie und Chemische Biologie, Technische Universität Dortmund, Dortmund, Germany.
  • 28 AbbVie, North Chicago, United States.
  • 29 The National Institute of Mental Health Psychoactive Active Drug Screening Program, University of North Carolina Chapel Hill School of Medicine, Chapel Hill, United States.
  • 30 National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, United States.
  • 31 Takeda Pharmaceutical Company Ltd., Fujisawa, Japan.
  • 32 Department of Biochemistry and Pharmacology, University of Massachusetts Medical School, Worcester, United States.
  • 33 Eurofins DiscoverX, Sane Diego, United States.
PMID: 29676732 DOI: 10.7554/eLife.34311
Abstract

Potent, selective and broadly characterized small molecule modulators of protein function (chemical probes) are powerful research reagents. The pharmaceutical industry has generated many high-quality chemical probes and several of these have been made available to academia. However, probe-associated data and control compounds, such as inactive structurally related molecules and their associated data, are generally not accessible. The lack of data and guidance makes it difficult for researchers to decide which chemical tools to choose. Several pharmaceutical companies (AbbVie, Bayer, Boehringer Ingelheim, Janssen, MSD, Pfizer, and Takeda) have therefore entered into a pre-competitive collaboration to make available a large number of innovative high-quality probes, including all probe-associated data, control compounds and recommendations on use (<ext-link ext-link-type="uri" xlink:href="https://openscienceprobes.sgc-frankfurt.de">https://openscienceprobes.sgc-frankfurt.de</ext-link><ext-link ext-link-type="uri" xlink:href="https://openscienceprobes.sgc-frankfurt.de/">/</ext-link>). Here we describe the chemical tools and target-related knowledge that have been made available, and encourage Others to join the project.

Keywords

Chemical probes; Open Science; Target validation; biochemistry; chemical biology.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-133083
    99.75%, c-Met Inhibitor